Diversification Versus Focus Dilemma Spotlights OTC Business Value
This article was originally published in The Tan Sheet
Executive Summary
As the pharmaceutical industry's revenue hole deepens, CEOs face two main routes: banking on innovation, or diversifying through generics, OTC and other non-core businesses
You may also be interested in...
Singulair Switch Among Merck's OTC Possibilities
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis
Singulair Switch Among Merck's OTC Possibilities
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis
Singulair Switch Among Merck's OTC Possibilities
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis